
Pharmacally
NSCLC
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in NSCLC
Health TidingsOncoC4 Reports 33% Response Rate with Cesalatamig in NSCLCOncoC4 reported a 33% objective response rate and 90% disease control rate with its investigational PD-1/VEGF bispecific antibody cesalatamig at 10 mg/kg in previously treated PD-(L)1-resistant or refractory…Fact-Checked
Fact-Checked
Clinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib CombinationHUTCHMED’s Phase III SANOVO trial found that savolitinib plus osimertinib extended median progression-free survival by 11.1 months versus osimertinib alone in previously untreated EGFR-mutated, MET-overexpressing advanced NSCLC.Fact-Checked
Health TidingsSystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NSCLCIzalontamab brengitecan nearly doubled median progression-free survival in the Phase 3 PANKU-Lung01 trial, reaching 11.1 months versus 5.7 months with platinum-based chemotherapy in previously treated EGFR-mutated non-small cell…Fact-Checked
Clinical TrialsORIC Plans Phase 3 After Positive Enozertinib Results in NSCLCORIC Pharmaceuticals reported an 84% investigator-assessed response rate and a 70% intracranial response rate with enozertinib in first-line EGFR atypical NSCLC.Fact-Checked
Health TidingsBH-30643 Shows 45% Response Rate in EGFR C797S NSCLCBlossomHill Therapeutics’ investigational BH-30643 demonstrated a 45% objective response rate and 88% disease control rate in patients with EGFR C797S-positive NSCLC who had developed resistance to prior EGFR…Fact-Checked
Health TidingsBlossomHill’s BH-30643 Gets FDA Fast Track Designation for EGFR C797S-Positive NSCLCBlossomHill Therapeutics’ investigational EGFR inhibitor BH-30643 has received FDA Fast Track designation for adults with advanced or metastatic EGFR C797S-positive non-small cell lung cancer after prior treatment with…Fact-Checked
Clinical TrialsAmplia and Lilly Partner to Advance Narmafotinib Plus Olomorasib for KRAS G12C-Mutant NSCLCAmplia Therapeutics has entered a clinical trial collaboration with Eli Lilly to evaluate the combination of the investigational FAK inhibitor narmafotinib and the KRAS G12C inhibitor olomorasib in…Fact-Checked
Clinical TrialsKairos Reports Favorable Safety Data for ENV-105 Plus Osimertinib in EGFR-Mutated NSCLCKairos Pharma has reported encouraging interim Phase 1 safety data for ENV-105 (carotuximab) combined with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Fact-Checked
Clinical TrialsKelun-Biotech Reports Positive Phase III OptiTROP-Lung06 Results in NSCLCKelun-Biotech reported positive Phase III OptiTROP-Lung06 results, with sacituzumab tirumotecan plus pembrolizumab significantly improving progression-free survival versus standard pembrolizumab and chemotherapy in first-line PD-L1-negative non-squamous NSCLC, supporting a…Fact-Checked
Clinical TrialsImmutep Reports 30.9-Month Overall Survival in Phase I INSIGHT-003 Trial of Efti for First-Line NSCLCImmutep reported mature Phase I INSIGHT-003 data showing a median overall survival of 30.9 months with eftilagimod alfa (efti) plus pembrolizumab and chemotherapy in first-line non-squamous NSCLC.Fact-Checked
Clinical TrialsMAIA Reports 90.5% Disease Control Rate with Ateganosine Plus Cemiplimab in NSCLC TrialMAIA Biotechnology has announced encouraging interim results from Part C of its Phase 2 THIO‑101 trial (NCT05208944), where the telomere‑targeting agent ateganosine achieved a 90.5% disease control rate…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.